Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in the Leerink Partners Global Healthcare Conference. The company's management will engage in a fireside chat on March 11, 2025 at 8:40 am ET in Miami, FL.
The presentation will be accessible via webcast through the company's website investor relations section and will remain available for replay for a minimum of 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – FULC
On the day this news was published, FULC declined 0.61%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025 at 8:40 am ET.
The webcast of the fireside chat will be accessible HERE and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Leerink Partners Conference 2025?
How can investors access Fulcrum Therapeutics' (FULC) Leerink Conference presentation?
How long will the replay of FULC's Leerink Conference presentation be available?
What is the focus of Fulcrum Therapeutics' (FULC) drug development program?
